Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders

International Journal of Developmental Neuroscience

Volumn 35, Issue , 2014, Pages 35-41

  Chen, Jianling ^a   Alberts, Ian ^c   Li, Xiaohong ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

AKT; Autism spectrum disorders; MTOR; Rett syndrome

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; FORKHEAD BOX PROTEIN G1; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; METHYL CPG BINDING PROTEIN 2; NEUROLIGIN; OXYTOCIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; RECOMBINANT SOMATOMEDIN C; REELIN; SEROTONIN TRANSPORTER; SOMATOMEDIN C; TUBERIN; UNCLASSIFIED DRUG; ONCOPROTEIN; TARGET OF RAPAMYCIN KINASE;

AUTISM; EARLY DIAGNOSIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; METABOLIC DISORDER; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NEWBORN SCREENING; NONHUMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RETT SYNDROME; REVIEW; ANIMAL; BRAIN; METABOLISM; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TOR SERINE-THREONINE KINASES;

EID: 84897457270     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2014.03.006     Document Type: Review

References (69)

1. Agoulnik I.U., Lee S.-L., et al. Functional role of mTORC2 versus integrin-linked kinase in mediating Ser473-Akt phosphorylation in PTEN-negative prostate and breast cancer cell lines. PLoS ONE 2013, 8(6):e67149.
2. Alessi D.R., Andjelkovic M., et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15(23):6541-6551.
3. Amir R.E., Van den Veyver I.B., et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23(2):185-188.
4. Anlar B., Oktem F., et al. Urinary epidermal and insulin-like growth factor excretion in autistic children. Neuropediatrics 2007, 38(3):151-153.
5. Anlar B., Sullivan K.A., et al. Insulin-like growth factor-I and central nervous system development. Horm. Metab. Res. 1999, 31(2-3):120-125.
6. Araghi-Niknam M., Fatemi S.H. Levels of Bcl-2 and P53 are altered in superior frontal and cerebellar cortices of autistic subjects. Cell. Mol. Neurobiol. 2003, 23(6):945-952.
7. Armstrong D.D. Rett syndrome neuropathology review 2000. Brain Dev. 2001, 23(Suppl. 1):S72L 76.
8. Armstrong D.D. Neuropathology of Rett syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8(2):72-76.
9. Balhara B., Misra M., et al. Recombinant human IGF-1 (insulin-like growth factor) therapy: where do we stand today?. Indian J. Pediatr. 2012, 79(2):244-249.
10. Benvenuto G., Li S., et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000, 19(54):6306-6316.
11. Beugnet A. Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J. Biol. Chem. 2003, 278(42):40717-40722.
12. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4(5):335-348.
13. Bolton P.F., Park R.J., et al. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 2002, 125(Pt 6):1247-1255.
14. Bozdagi O., Tavassoli T., et al. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol. Autism 2013, 4(1):9.
15. Chalhoub N., Zhu G., et al. Cell type specificity of PI3K signaling in Pdk1- and Pten-deficient brains. Genes Dev. 2009, 23(14):1619-1624.
16. Cheng E.H., Wei M.C., et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 2001, 8(3):705-711.
17. Culmsee C., Mattson M.P. p53 in neuronal apoptosis. Biochem. Biophys. Res. Commun. 2005, 331(3):761-777.
18. Dastidar S.G., Bardai F.H., et al. Isoform-specific toxicity of Mecp2 in postmitotic neurons: suppression of neurotoxicity by FoxG1. J. Neurosci. 2012, 32(8):2846-2855.
19. Dastidar S.G., Landrieu P.M., et al. FoxG1 promotes the survival of postmitotic neurons. J. Neurosci. 2011, 31(2):402-413.
20. De Paula M.L., Cui Q.-L., et al. The PTEN inhibitor bisperoxovanadium enhances myelination by amplifying IGF-1 signaling in rat and human oligodendrocyte progenitors. Glia 2014, 62(1):64-77.
21. Ehninger D., Han S., et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 2008, 14(8):843-848.
22. Evans J.C., Archer H.L., et al. Variation in exon 1 coding region and promoter of MECP2 in Rett syndrome and controls. Eur. J. Hum. Genet. 2005, 13(1):124-126.
23. Fombonne E., Roge B., et al. Microcephaly and macrocephaly in autism. J. Autism Dev. Disord. 1999, 29(2):113-119.
24. Frias M.A., Thoreen C.C., et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 2006, 16(18):1865-1870.
25. Garza L., Aude Y.W., et al. Can we prevent in-stent restenosis?. Curr. Opin. Cardiol. 2002, 17(5):518-525.
26. Gozzi M., Nielson D.M., et al. A magnetization transfer imaging study of corpus callosum myelination in young children with autism. Biol. Psychiatry 2012, 72(3):215-220.
27. Hagberg B. Rett's syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr. Scand. 1985, 74(3):405-408.
28. Hay N. Upstream and downstream of mTOR. Genes Dev. 2004, 18(16):1926-1945.
29. Huang S., Houghton P.J. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 2003, 3(4):371-377.
30. Hunt A., Shepherd C. A prevalence study of autism in tuberous sclerosis. J. Autism Dev. Disord. 1993, 23(2):323-339.
31. Inoki K. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17(15):1829-1834.
32. Kim D.H., Sarbassov D.D., et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 2003, 11(4):895-904.
33. Kim J.E., Shin M.S., et al. Treadmill exercise ameliorates motor disturbance through inhibition of apoptosis in the cerebellum of valproic acid-induced autistic rat pups. Mol. Med. Rep. 2013, 8(2):327-334.
34. Kwon C.H., Luikart B.W., et al. Pten regulates neuronal arborization and social interaction in mice. Neuron 2006, 50(3):377-388.
35. Laviola L., Natalicchio A., et al. The IGF-I signaling pathway. Curr. Pharm. Des. 2007, 13(7):663-669.
36. Leevers S.J., Vanhaesebroeck B., et al. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr. Opin. Cell Biol. 1999, 11(2):219-225.
37. Li J., Yen C., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947.
38. Li X., Zou H., et al. Genes associated with autism spectrum disorder. Brain Res. Bull. 2012, 88(6):543-552.
39. Li Y., Wang H., et al. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 2013, 13(4):446-458.
40. Lv J.-W., Cheng T.-L., et al. Role of the PTEN signaling pathway in autism spectrum disorder. Neurosci. Bull. 2013, 29(6):773-778.
41. Makkonen I., Kokki H., et al. Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism. Neuropediatrics 2011, 42(5):207-209.
42. Mencarelli M.A., Spanhol-Rosseto A., et al. Novel FOXG1 mutations associated with the congenital variant of Rett syndrome. J. Med. Genet. 2010, 47(1):49-53.
43. Midyett L.K., Rogol A.D., et al. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 2010, 95(2):611-619.
44. Mills J.L., Hediger M.L., et al. Elevated levels of growth-related hormones in autism and autism spectrum disorder. Clin. Endocrinol. (Oxf.) 2007, 67(2):230-237.
45. Napoli E., Ross-Inta C., et al. Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53. PLoS ONE 2012, 7(8):e42504.
46. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 2013, 31:675-704.
47. Pópulo H., Lopes J.M., et al. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 2012, 13(12):1886-1918.
48. Rastegar M., Hotta A., et al. MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy. PLoS ONE 2009, 4(8):e6810.
49. Regad T., Roth M., et al. The neural progenitor-specifying activity of FoxG1 is antagonistically regulated by CKI and FGF. Nat. Cell Biol. 2007, 9(5):531-540.
50. Ricciardi S., Boggio E.M., et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum. Mol. Genet. 2011, 20(6):1182-1196.
51. Riikonen R., Makkonen I., et al. Cerebrospinal fluid insulin-like growth factors IGF-1 and IGF-2 in infantile autism. Dev. Med. Child Neurol. 2006, 48(9):751-755.
52. Rinderknecht E., Humbel R.E. Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. Proc. Natl. Acad. Sci. U. S. A. 1976, 73(7):2365-2369.
53. Salmon W.D., Daughaday W.H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J. Lab. Clin. Med. 1957, 49(6):825-836.
54. Sarbassov D.D., Ali S.M., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14(14):1296-1302.
55. Sato A., Kasai S., et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat. Commun. 2012, 3:1292.
56. Schaevitz L.R., Moriuchi J.M., et al. Cognitive and social functions and growth factors in a mouse model of Rett syndrome. Physiol. Behav. 2010, 100(3):255-263.
57. Seo T.-B., Cho H.-S., et al. Treadmill exercise improves behavioral outcomes and spatial learning memory through up-regulation of reelin signaling pathway in autistic rats. J. Exerc. Rehabil. 2013, 9(2):220-229.
58. Sheikh A.M., Malik M., et al. BDNF-Akt-Bcl2 antiapoptotic signaling pathway is compromised in the brain of autistic subjects. J. Neurosci. Res. 2010, 88(12):2641-2647.
59. Smalley S.L. Autism and tuberous sclerosis. J. Autism Dev. Disord. 1998, 28(5):407-414.
60. Sperow M., Berry R.B., et al. Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration. J. Physiol. 2012, 590(Pt 4):777-792.
61. Steinman G., Mankuta D. Insulin-like growth factor and the etiology of autism. Med. Hypotheses 2013, 80(4):475-480.
62. Tropea D., Giacometti E., et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(6):2029-2034.
63. Vanhala R., Turpeinen U., et al. Insulin-like growth factor-I in cerebrospinal fluid and serum in Rett syndrome. J. Child Neurol. 2000, 15(12):797-802.
64. Vanhala R., Turpeinen U., et al. Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism. Dev. Med. Child Neurol. 2001, 43(9):614-616.
65. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2(7):489-501.
66. Whitman M., Kaplan D.R., et al. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985, 315(6016):239-242.
67. Ye P., Li L., et al. Myelination is altered in insulin-like growth factor-I null mutant mice. J. Neurosci. 2002, 22(14):6041-6051.
68. Zhou J., Blundell J., et al. Pharmacological Inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J. Neurosci. 2009, 29(6):1773-1783.
69. Zoncu R., Efeyan A., et al. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2010, 12(1):21-35.